Theriva Biologics
TOVX
20 hedge funds and large institutions have $1.37M invested in Theriva Biologics in 2024 Q1 according to their latest regulatory filings, with 4 funds opening new positions, 1 increasing their positions, 4 reducing their positions, and 4 closing their positions.
202% more capital invested
Capital invested by funds: $452K → $1.37M (+$914K)
0% more funds holding
Funds holding: 20 → 20 (0)
0% more first-time investments, than exits
New positions opened: 4 | Existing positions closed: 4
0.06% less ownership
Funds ownership: 0.25% → 0.18% (-0.06%)
75% less repeat investments, than reductions
Existing positions increased: 1 | Existing positions reduced: 4
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
TSS
Two Sigma Securities
New York
|
+$9.96K |
| 2 |
SAG
SageView Advisory Group
Newport Beach,
California
|
+$4.88K |
| 3 |
Renaissance Technologies
New York
|
+$4.35K |
| 4 |
IHWM
Iron Horse Wealth Management
Johston,
Iowa
|
+$176 |
| 5 |
OPTFSNA
Old Point Trust & Financial Services N A
Newport News,
Virginia
|
+$47 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
-$66.1K |
| 2 |
Jane Street
New York
|
-$20.5K |
| 3 |
VF
Virtu Financial
New York
|
-$17K |
| 4 |
Citadel Advisors
Miami,
Florida
|
-$15.6K |
| 5 |
BCM
Bridgeway Capital Management
Houston,
Texas
|
-$12.3K |
TOVX Hedge Fund Activity: Q1 2024 in Review
20 of the 6,942 institutional investors tracked by Wall St. Rank reported a position in Theriva Biologics (TOVX) for Q1 2024, worth a combined $1.37M — up 202% from $452K a quarter earlier.
Fund positioning in TOVX was balanced in Q1 2024: 4 funds opened new positions, 4 closed out, 1 added to existing stakes and 4 trimmed.
The largest buyer was Two Sigma Securities, opening a new position worth an estimated $9.96K. The largest seller was Vanguard Group, cutting an estimated $66.1K.
- 20 institutional investors held Theriva Biologics (TOVX) as of Q1 2024, unchanged from Q4 2023.
- Funds reported $1.37M of Theriva Biologics stock for Q1 2024, up 202% quarter-over-quarter.
- 4 funds opened new Theriva Biologics positions in Q1 2024 and 4 closed out, a net change of 0 holders.
- The largest Theriva Biologics buyer in Q1 2024 was Two Sigma Securities, an estimated $9.96K added.
- The largest Theriva Biologics seller in Q1 2024 was Vanguard Group, an estimated $66.1K sold.
Based on aggregated 13F filings for Q1 2024.